UF Innovate | Accelerate resident client NeXtGen Biologics announced the successful completion of a two-day inspection by the U.S. Food and Drug Administration (FDA). The inspection concluded with no Form 483 observations issued, underscoring the company’s commitment to quality, compliance, and operational excellence.
“Our vision has always been to pair scientific innovation with uncompromising integrity,” said Jonelle Toothman, co-founder and CEO of NeXtGen Biologics. “Completing this inspection with no observations highlights both the rigor of our quality systems and the high standards our team holds in every aspect of their work.”
Read more about NeXtGen Biologics Successfully Completes First FDA Audit With Zero 483 Observations.
